Literature DB >> 3924086

Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.

D Overbosch, H Mattie, R van Furth.   

Abstract

In this study the antimicrobial effects of phenoxymethylpenicillin (PM) and pheneticillin (PE) in vitro and in an experimental animal infection model were compared as well as the pharmacokinetic properties of both drugs in patients. For the inhibitory effect of PM on short-term (3 h) growth of S. aureus in vitro, this drug was 2.13 times more potent than PE. The protein binding of both drugs was similar (78-80%). The potency ratio of PM to PE against S. aureus in an experimental mouse-thigh infection was only 1.25 to 1. This is explained by the difference in the AUC after subcutaneous administration of PM (0.47 mg 1(-1) h) and PE (0.92 mg 1(-1) h). The plasma clearance after intravenous administration of PM was 476.4 ml/min and that of PE was 295.1 ml/min; the plasma clearance of both drugs was strongly correlated with the creatinine clearance. The volume of distribution in the steady state of PM was 35.41 and that of PE 22.51. In 10 patients, the absorption after oral administration of PM as the acid was 48% and that of the potassium salt of PE was 86% of the dose. From the present results it can be concluded that a difference in effectiveness of different formulations of PM and PE would depend entirely on differences in absorption.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924086      PMCID: PMC1463849          DOI: 10.1111/j.1365-2125.1985.tb02693.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  A COMPARISON OF FOUR PHENOXYPENICILLINS.

Authors:  J M BOND; M BARBER; J W LIGHTBOWN; P M WATERWORTH
Journal:  Br Med J       Date:  1963-10-19

2.  The relative antibacterial activity of four penicillins.

Authors:  L P GARROD
Journal:  Br Med J       Date:  1960-12-10

3.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

4.  Computer-assisted prescribing of kanamycin for patients with renal insufficiency.

Authors:  G E Mawer; S B Lucas; B R Knowles; R M Stirland
Journal:  Lancet       Date:  1972-01-01       Impact factor: 79.321

5.  Influence of lipophilic character on the antibacterial activity of cephalosporins and penicillins.

Authors:  G L Biagi; M C Guerra; A M Barbaro; M F Gamba
Journal:  J Med Chem       Date:  1970-05       Impact factor: 7.446

6.  Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum.

Authors:  C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1966 Mar-Apr       Impact factor: 6.875

7.  New method for calculating the intrinsic absorption rate of drugs.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

Review 8.  Phenoxymethylpenicillin (penicillin V) and phenethicillin.

Authors:  L D Sabath
Journal:  Med Clin North Am       Date:  1970-09       Impact factor: 5.456

9.  A comparative study of blood concentrations after peroral benzathine (DBED) penicillin V and potassium penicillin V.

Authors:  I Palatsi; W Kaipainen
Journal:  Scand J Infect Dis       Date:  1971
View more
  3 in total

1.  The importance of pharmacokinetics and pharmacodynamics for effective treatment of infections.

Authors:  H Mattie
Journal:  Clin Investig       Date:  1993-06

2.  Milk transfer of phenoxymethylpenicillin during puerperal mastitis.

Authors:  I Matheson; M Samseth; R Løberg; A Faegri; A Prentice
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.

Authors:  Arantxa Isla; Andrés Canut; Alicia R Gascón; Alicia Labora; Bruno Ardanza-Trevijano; Maria Angelés Solinís; Jose Luis Pedraz
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.